Evidence map›Paper›PMID 40417828›Full record

ArticleHuman vaccines & immunotherapeutics2025

rLVS Δ

Qingmei Jia, Richard A Bowen, Saša Masleša-Galić, Marcus A Horwitz

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Anti-infective compounds forSustainable microbiology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Qingmei JiaDivision of Infectious Diseases, Department of Medicine, 32-150 Center for Health Sciences, School of Medicine, University of California - Los Angeles, Los Angeles, CA, USA.ORCID 0000-0002-2328-4806
Richard A BowenDepartment of Biomedical Sciences, Colorado State University, Fort Collins, CO, USA.ORCID 0000-0002-7576-2881
Saša Masleša-GalićDivision of Infectious Diseases, Department of Medicine, 32-150 Center for Health Sciences, School of Medicine, University of California - Los Angeles, Los Angeles, CA, USA.
Marcus A HorwitzDivision of Infectious Diseases, Department of Medicine, 32-150 Center for Health Sciences, School of Medicine, University of California - Los Angeles, Los Angeles, CA, USA.ORCID 0000-0001-6525-7147

Funding

Development of a Safe and Potent Vaccine Against Melioidosis using the LVS dcapB Vector PlatformR01AI141390 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI HORWITZ, MARCUS AARON · 2019 to 2023
$3.9M
NIAID NIH HHS R01 AI141390
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antigens, BacterialBacterial ProteinsFimbriae ProteinsPlaguePlague VaccinePore Forming Cytotoxic ProteinsYersinia pestisAnimalsAntibodies, BacterialDisease Models, AnimalFemaleFrancisella tularensisGenetic VectorsImmunization, SecondaryMiceMice, Inbred BALB CAntibodies, BacterialAntigens, BacterialBacterial Proteinscaf1 protein, Yersinia pestisFimbriae ProteinsLcrV protein, YersiniaPlague VaccinePore Forming Cytotoxic ProteinsVaccines, AttenuatedVaccines, SyntheticbioterrorismF1Francisella tularensisLcrVLVS ΔcapBplaguesingle vector platform vaccineTier 1 select agentVaccineYersinia pestis

Identifiers

PMID40417828
PMCPMC12118393

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.